Ipilimumamb is SOC now but, BMY has gone much ahead with nivolumab and combination nivolumab + ipilimumab which has shown 94% OS after 1 year and 88% after 2 years in metastatic stage 4 malenoma, doubling OS as single agent, which had already shown an significant improvement against previous SOC and wqhich will become SOC shortly.
These checkpoint inhibitors are being tested also with other cancers and will most likely become SOC also there. Without mentioning Merck with its latest approval of petrolizumab.
It is not a matter of risk appetite, I like for instance AMRN , where I moved the NWBO funds yesterday.
News 
Market Data 
Discover 
AI
